 |
Product
Name: Avodart
Product Type: Dutasteride 0.5 mg
Manufacturer: GlaxoSmithKline
Packaging and Product: Each packet contains 30
gel caps
Product Classification: Prescription Medication
Clinical studies have shown dutasteride to be more
effective than Propecia in blocking the hormone
DHT responsible for hair loss. |
 |
|
| Product
Price List |
1
Packet of Avodart 0.5 mg - (30
Gel Caps)
|
US $ 79.00 |
2
Packets of Avodart 0.5 mg - (60
Gel Caps)
|
US $154.00 |
3
Packets of Avodart 0.5 mg - (90
Gel Caps)
|
US $225.00 |
| 4
Packets of Avodart 0.5 mg - (120
Gel Caps) |
US $290.00 |
|
|
|
| Avodart
(Dutasteride 0.5 mg) |
| GI198745
or Dutasteride as we now call it is a new drug developed by
GlaxoSmithKline to treat BPH or Benign Prostatic Hyperplasia
(enlarged prostate) and MPB, Male Pattern Baldness. |
| Since
DHT is the cause of both of these conditions, the drug works
by preventing the DHT from being created in the first place.
The 5 alpha reductase enzyme is responsible for turning
Testosterone in Dihydrotestosterone (DHT), and the drug works
by preventing this chemical change from taking place. |
| The
reason why this drug is so important is that it inhibits both
5-AR type 1 and 5 AR type 2, unlike Propecia (Finasteride),
which inhibits just type 2. |
| It
is believed that type 1 is still responsible for about 20% of
the DHT that is not eliminated by Propecia and may be the
reason why some men do not respond to Propecia, which only
inhibits type 2. |
| Clinical
Results |
| These
are the results of the GlaxoSmithKline testing of GI198745
otherwise known as Dutasteride for hair loss. These results
were taken from the Phase II study required for FDA approval.
The Phase III trials for hair loss are currently on hold,
though the FDA recently approved Avodart to treat BPH. |
| These
are the results of the GlaxoSmithKline testing of GI198745
otherwise known as Dutasteride for hair loss. These results
were taken from the Phase II study required for FDA approval.
The Phase III trials for hair loss are currently on hold, but
the NDA (New Drug Application) for BPH was submitted to the
FDA in December 2000. This mean that if approved by the FDA,
Dutasteride could be available by the end of 2001 or early
2002 for the treatment of an enlarged prostate or BPH. |
| |
